| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ART4 |
| Uniprot No | Q93070 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 47-285aa |
| 氨基酸序列 | ADPSEVAIKIDFDFAPGSFDDQYQGCSKQVMEKLTQGDYFTKDIEAQKNY FRMWQKAHLAWLNQGKVLPQNMTTTHAVAILFYTLNSNVHSDFTRAMASV ARTPQQYERSFHFKYLHYYLTSAIQLLRKDSIMENGTLCYEVHYRTKDVH FNAYTGATIRFGQFLSTSLLKEEAQEFGNQTLFTIFTCLGAPVQYFSLKK EVLIPPYELFKVINMSYHPRGDWLQLRSTGNLSTYNCQLLKAHHHHHH |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ART4重组蛋白的虚构示例参考文献(仅作格式示例，非真实文献)：
1. **文献名称**：Structural and Functional Analysis of ART4 Recombinant Protein in Cancer Cell Lines
**作者**：Li, X. et al.
**摘要**：研究利用重组ART4蛋白解析其ADP-核糖基转移酶活性，发现其在胃癌细胞中通过调控EGFR信号通路促进肿瘤增殖，为靶向治疗提供依据。
2. **文献名称**：ART4 as a Novel Tumor Antigen for Immunotherapy in Hematologic Malignancies
**作者**：Müller, S. & Schmidt, T.
**摘要**：通过重组ART4蛋白验证其在急性髓系白血病细胞表面高表达，开发基于ART4的CAR-T细胞疗法，并在小鼠模型中显著抑制肿瘤生长。
3. **文献名称**：Crystallographic Characterization of Recombinant Human ART4 Protein
**作者**：Zhang, Y. et al.
**摘要**：首次报道人源ART4重组蛋白的X射线晶体结构(分辨率2.1Å)，揭示其底物结合域的关键氨基酸残基，为酶活性机制研究奠定结构基础。
4. **文献名称**：ART4-Mediated Resistance to Chemotherapeutic Agents in Colorectal Cancer
**作者**：Park, J.H. et al.
**摘要**：发现重组ART4蛋白通过增强DNA修复能力导致结直肠癌细胞对5-氟尿嘧啶耐药，沉默ART4可恢复化疗敏感性。
---
**注**：以上文献为示例性内容，实际研究中请通过PubMed/Google Scholar等平台检索真实文献。
ART4 (ADP-ribosyltransferase 4), also known as CD297 or Dombrock blood group glycoprotein, is a cell surface protein encoded by the ART4 gene in humans. It belongs to the ADP-ribosyltransferase family, though its enzymatic activity remains debated due to structural variations in its catalytic domain. Unlike other family members, ART4 lacks conserved residues critical for NAD+ substrate binding, suggesting it may function as a non-enzymatic receptor or adhesion molecule.
Primarily expressed on erythrocytes, ART4 serves as a carrier of the Dombrock blood group antigens (Doa and Dob). These antigens are clinically relevant in transfusion medicine, as mismatches can trigger hemolytic reactions. Recombinant ART4 protein is thus utilized in blood typing assays and antibody screening. Beyond red blood cells, ART4 is detected in skeletal muscle, heart, colon, and immune cells, implying broader roles in cell signaling or tissue homeostasis.
Structurally, ART4 is a glycosylphosphatidylinositol (GPI)-anchored protein with two extracellular ADP-ribosyltransferase-like domains. Its GPI linkage enables dynamic membrane localization and potential participation in lipid raft-mediated signaling. Studies suggest interactions with extracellular ligands or membrane proteins, though specific binding partners remain uncharacterized.
Recombinant ART4 production typically employs mammalian or insect cell systems to ensure proper post-translational modifications, including glycosylation. Applications include serological diagnostics, autoimmune disease research (e.g., ART4 autoantibodies in pemphigus), and investigations into its biological functions. Recent interest explores its potential as a therapeutic target or biomarker in cancers where ART4 shows aberrant expression.
Despite progress, ART4's physiological role remains enigmatic, warranting further studies to elucidate its molecular mechanisms and pathophysiological significance.
×
